CAMBRIDGE, Mass, August 15, 2016 – Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced today that Ankit Mahadevia, President and CEO, will present a company overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 8:00 a.m. ET in New York, NY.
Spero is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections and is located in Cambridge, Massachusetts. The company’s pipeline of anti-infective agents is one of the most unique in the industry. Spero is pioneering an entirely new therapeutic platform; this approach has yielded multiple molecules that enhance the utility and potency of many classes of existing drugs to include possible utility against Gram-negative pathogens. Spero’s DHFR (oral ESBL) program is exploring the expansion of a novel antifolate’s antibacterial spectrum to treat trimethoprim resistance isolates including Gram-negative pathogens. The investors in Spero include Atlas Ventures, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group, Osage Partners and The Partners Innovation Fund. For more information, please visit www.sperotherapeutics.com
Spectrum Science Communications:
Maia Arnold, PhD
Senior Scientific Executive
Stern Investor Relations
Beth DelGiacco, Vice President